Loading
ZST-101 is an experimental radioactive medicine from ZEeST Bio for hepatocellular carcinoma, the commonest primary liver cancer. It is in laboratory testing.
ZST-101 is the lead programme of ZEeST Bio, a radiotherapeutic built on a theranostic radiopharmaceutical platform for hepatocellular carcinoma, listed as preclinical on the company's pipeline. No clinical data exist.
A radiopharmaceutical carried into liver tumours by a clinically validated hepatotropic uptake mechanism, designed for both imaging and therapy, as the developer describes.
1.ZST-101 binds its target on the cancer cell or is taken up by it.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ZST-101" OR ABSTRACT:"ZST-101") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZST-101, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/